ClinicalTrials.gov
ClinicalTrials.gov Menu

Cyclic Exclusive Enteral Nutrition as Maintenance Therapy for Pediatric Crohn's Disease (CD-HOPE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02201693
Recruitment Status : Recruiting
First Posted : July 28, 2014
Last Update Posted : December 21, 2017
Sponsor:
Collaborator:
GETAID pédiatrique
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:
The purpose of this study is to compare the rate of first relapse at 12 months between maintenance therapy with cyclic exclusive enteral nutrition (EEN) (at least 100% daily calories) and maintenance therapy with supplementary enteral nutritional support (25% daily calories).

Condition or disease Intervention/treatment Phase
Crohn's Disease Dietary Supplement: MODULEN IBD Not Applicable

Detailed Description:

Enteral nutrition (EN) is a highly efficacious treatment option for Crohn's disease (CD). In children, exclusive EN is considered first choice therapy to induce remission in pediatric CD, as highlighted in the recent ESPGHAN-ECCO guidelines. Several meta-analyses showed that the anti-inflammatory potential of EEN is comparable to the effects of steroids. In addition, children with CD often have marked growth retardation and EEN is one of the most efficacious treatment options to induce catch-up growth in these patients. There is convincing data indicating that EN is highly efficacious when given on an exclusive basis, while the use of partial EN is markedly less effective to induce remission in active Crohn's disease as compared to exclusive EN. Recently, it was suggested that exclusive EN has a dominant effect on the intestinal microbiota, which contributes to the induction of remission. There exists several strategies to maintain remission in children with CD, but there is no clear consensus on which maintenance treatment to follow. There are some indicators to believe that enteral nutritional therapy might play also a significant role as maintenance therapy for CD. Given the fact that many centers use a top-down approach with the introduction of immunosuppressors and/or biologics at/or shortly after diagnosis, the investigators wanted to test the possibility of a treatment option to efficiently maintain remission with less (or no) side effects based on enteral nutrition to avoid the early use of immunosuppressors.

It's a French multicenter, prospective, randomized study with PROBE (prospective randomized open blind end-point) evaluation. Randomization will be performed in a blinded and centralized manner, allocating patients to one of the two treatment groups :

  • ARM A : Cyclic exclusive MODULEN IBD for 2 weeks every 8 weeks
  • ARM B: MODULEN IBD supplementation (25% of caloric requirements) alone

A Physician not involved in the study design and blinded to the treatment arm will perform the evaluation of the patients during each study visit.

A total of four visits (including final visit) are scheduled for this trial over a period of 12 months at a rhythm of every three months (+/- 2 weeks) for all patients. The study visit will happen during scheduled routine visits, necessary for the routine care of CD patients. Each visit comprises a routine clinical evaluation. The assessment of maintenance of remission is particularly important (wPCDAI<12.5 points), a routine lab analysis including fecal calprotectin is required at each visit. In addition, all relevant medical or other events will be recorded. Only for patients who participate in the annex studies an additional stool sample (microbial analysis) is required. At M9 visit, follow-up endoscopy (M12+/- 6weeks) and entero-MRI (M12+/- 6 weeks) will be programmed as part of the routine surveillance of patients on maintenance therapy, allowing to adjust treatment in the following if necessary. Compliance to treatment will be monitored by recordings of daily MODULEN IBD intake during 2 week periods on the E-system. A quality of life E-questionnaire will be filled out one day prior to each visit.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomised Trial Comparing 12 Months of Cyclic Enteral Nutrition to Supplementary Enteral Nutrition as Maintenance Therapy for Pediatric Crohn's Disease
Actual Study Start Date : December 12, 2014
Estimated Primary Completion Date : March 2019
Estimated Study Completion Date : June 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Crohn's Disease

Arm Intervention/treatment
Experimental: Cyclic exclusive MODULEN IBD
Cyclic exclusive MODULEN IBD for 2 weeks every 8 weeks
Dietary Supplement: MODULEN IBD
2 week ON / 6 weeks OFF treatment every 8 weeks covering at least 100% of daily caloric requirement (approx. 2-2.5L/day).

Experimental: MODULEN IBD supplementation (25% of caloric requirements)
MODULEN IBD supplementation (25% of caloric requirements) alone A Physician not involved in the study design and blinded to the treatment arm will perform the evaluation of the patients during each study visit.
Dietary Supplement: MODULEN IBD
25% of daily caloric requirements, approx. 500mL/day




Primary Outcome Measures :
  1. The first relapse [ Time Frame: 12 months ]
    Assessed with wPCDAI


Secondary Outcome Measures :
  1. Clinical remission [ Time Frame: 12 months ]
    Assessed with wPCDAI, CDAI, PGA

  2. Time to the first relapse [ Time Frame: until month 12 ]
    Assessed with wPCDAI, CDAI, PGA

  3. Variation of wPCDAI, [ Time Frame: until month12 ]
    Assessed with wPCDAI

  4. Endoscopic remission [ Time Frame: month 12 ]
    CDEIS

  5. Transmural healing [ Time Frame: Month 12 ]
    MRI

  6. Calprotectin [ Time Frame: until month12 ]
    Fecal sample

  7. Quality of life analysis [ Time Frame: Until Month 12 ]
    E-questionnaire

  8. Growth pattern [ Time Frame: Until Month 12 ]
    Z-Score



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   6 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 6-18 years
  • Confirmed Crohn's disease (L1, L2, L3+/- L4a/b)
  • new-onset disease or acute relapse treated with enteral nutrition
  • responding to induction therapy with exclusive enteral nutrition with complete clinical remission at inclusion visit (wPCDAI<12.5)
  • completed cycle of induction therapy of at least 6 weeks (6-12 weeks)
  • biological treatment by Remicade has to be stopped at least 8 weeks prior to inclusion
  • "wash out" of corticosteroids, immunosuppressors and treatment by Humira of minimally 4 weeks prior to inclusion
  • 5-ASA and derivates have to be stopped at least at screening visit
  • Antibiotics must be stopped at least 2 weeks prior to inclusion
  • Informed and signed consent

Exclusion Criteria:

  • Patients with B2 or B3 disease behavior (intestinal/colonic stenosis (including ileo-caecal valve), intrabdominal abscess, fistulizing disease)
  • Patients not in remission on induction therapy (wPCDAI>12.5)
  • Patients with isolated and severe perianal disease
  • Patients requiring surgical therapy at inclusion
  • Ongoing steroid medication
  • Ongoing immunosuppressor or biologics therapy
  • No informed consent
  • Currently participating or having participated in another interventional clinical trial during the last 4 weeks prior to the beginning of this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02201693


Contacts
Contact: Frank RUEMMELE, MD, PhD +33 1. 44.49.25.16 frank.ruemmele@nck.aphp.fr
Contact: Laurence Lecomte +33 171 196494 laurence.lecomte@nck.aphp.fr

Locations
France
Hôpital Necker - Enfants Malades Recruiting
Paris, France, 75015
Contact: Laurence lecomte, PhD    +33 1 71 19 64 94    laurence.lecomte@nck.aphp.fr   
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
GETAID pédiatrique
Investigators
Principal Investigator: Franck RUEMMELE, MD, PhD Assistance Publique - Hôpitaux de Paris

Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT02201693     History of Changes
Other Study ID Numbers: P130302
2013-A01473-42 ( Other Identifier: ANSM )
First Posted: July 28, 2014    Key Record Dates
Last Update Posted: December 21, 2017
Last Verified: December 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Crohn's disease,
pediatric GETAID (Therapeutic study group of inflammatory bowel diseases of the child),
enteral nutrition,
randomized multicenter study

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases